WO2017183665A1 - 制御性t細胞の活性化剤及びその使用 - Google Patents
制御性t細胞の活性化剤及びその使用 Download PDFInfo
- Publication number
- WO2017183665A1 WO2017183665A1 PCT/JP2017/015767 JP2017015767W WO2017183665A1 WO 2017183665 A1 WO2017183665 A1 WO 2017183665A1 JP 2017015767 W JP2017015767 W JP 2017015767W WO 2017183665 A1 WO2017183665 A1 WO 2017183665A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- dnam
- seq
- acid sequence
- human
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to an activator of regulatory T cells and use thereof. More specifically, an activator of regulatory T cells, a pharmaceutical composition for activating regulatory T cells, an anti-human DNAX Accessory Molecule-1 (DNAM-1) monoclonal antibody or fragment thereof, a nucleic acid, a vector, and transformation About the body.
- DNAM-1 DNAX Accessory Molecule-1
- Graft-versus-host disease may develop after blood transfusion or stem cell transplantation.
- Graft-versus-host disease occurs when activated T cells from a donor present in the transplanted cells damage the recipient's cells.
- rejection may occur when a donor organ is transplanted into a recipient.
- the transplanted heart, blood vessel, and kidney may be temporarily engrafted, but detachment may be gradually observed. For this reason, a technique for suppressing graft-versus-host disease and organ transplant rejection is required.
- Patent Document 1 describes that a neutralizing antibody against mouse DNAM-1 protein can be used as a drug for maintaining engraftment of transplanted heart, transplanted blood vessel or transplanted kidney in mice.
- the DNAM-1 protein is an adhesion molecule belonging to the immunoglobulin superfamily with a molecular weight of 65 kDa, also called CD226. Expression of DNAM-1 protein is observed in various immune cells such as human and mouse CD4 + T cells, CD8 + T cells, NK cells, macrophages and dendritic cells.
- the RefSeq ID of human DNAM-1 is NP_001290547, and the RefSeq ID of mouse DNAM-1 is NP_001034238.
- the inventors have previously shown that the DNAM-1 protein binds to CD155, which has been known as the poliovirus receptor.
- CD155 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily.
- an object of the present invention is to provide a technique capable of suppressing a human immune reaction.
- a regulatory T cell activator comprising a substance that inhibits the binding of DNAM-1 and CD155.
- the substance that inhibits the binding between DNAM-1 and CD155 is a specific binding substance for DNAM-1, a DNAM-1 expression inhibitor, a specific binding substance for CD155, or a CD155 expression inhibitor.
- the substance that inhibits the binding of DNAM-1 and CD155 is a specific binding substance for DNAM-1, the DNAM-1 is human DNAM-1, and the specific binding substance is an antibody or a fragment thereof
- the antibody or fragment thereof is a human DNAM-1 molecule present on the surface of 1 ⁇ 10 5 lymphocytes in which human DNAM-1 is forcibly expressed.
- the binding between the fusion protein and the human DNA M-1 molecule can be completely inhibited at 500 ng or less in terms of the total length of the IgG antibody.
- the activator of regulatory T cells according to any one of [4] to [4].
- CDRs 1 to 3 are heavy chains consisting of the amino acid sequences of SEQ ID NOs: 1 to 3, respectively. Any of [4] to [6], wherein the variable region and CDRs 1 to 3 compete with an antibody having a light chain variable region consisting of the amino acid sequences of SEQ ID NOs: 4 to 6, respectively.
- CDRs 1 to 3 are amino acids in which one or several amino acids have been deleted, substituted, or added in the amino acid sequence of SEQ ID NOs: 1 to 3 or the amino acid sequences of SEQ ID NOs: 1 to 3, respectively.
- a heavy chain variable region comprising the sequences and CDRs 1 to 3 are amino acids in which one or several amino acids have been deleted, substituted or added in the amino acid sequences of SEQ ID NOs: 4 to 6 or amino acid sequences of SEQ ID NOs: 4 to 6, respectively.
- a pharmaceutical composition for activating regulatory T cells, comprising the regulatory T cell activator according to any one of [1] to [8] and a pharmaceutically acceptable carrier.
- the total amount is 100 ng or less in terms of the total length of an IgG-type antibody.
- CDRs 1 to 3 are amino acid sequences of SEQ ID NOs: 1 to 3 or amino acid sequences in which one or several amino acids are deleted, substituted, or added in the amino acid sequences of SEQ ID NOs: 1 to 3, respectively.
- CDRs 1 to 3 are amino acid sequences of SEQ ID NOs: 4 to 6 or amino acid sequences of SEQ ID NOs: 4 to 6, respectively, wherein one or several amino acids are deleted, substituted, or added to the light chain variable region.
- CDR1 to CDR3 are each a heavy chain variable region consisting of the amino acid sequence of SEQ ID NOS: 1 to 3, and CDR1 to 3 are respectively SEQ ID NO: 4.
- CDRs 1 to 3 each have a heavy chain variable region consisting of an amino acid sequence of SEQ ID NOs: 1 to 3
- CDRs 1 to 3 each have a light chain variable region consisting of an amino acid sequence of SEQ ID NOs: 4 to 6,
- the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 or the amino acid sequence of SEQ ID NO: 7 in which one or several amino acids are deleted, substituted or added, and the amino acid sequence of SEQ ID NO: 8,
- the anti-chain according to any one of [10] to [15], which has a light chain variable region consisting of an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 8.
- the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 9, or the amino acid sequence of SEQ ID NO: 9, wherein one or several amino acids are deleted, substituted or added, and the amino acid sequence of SEQ ID NO: 10, or
- the anti-human DNAM according to any one of [10] to [14], which has a light chain variable region consisting of an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence of SEQ ID NO: 10 -1 Monoclonal antibody or fragment thereof.
- CDRs 1 to 3 are amino acid sequences of SEQ ID NOs: 1 to 3 or amino acid sequences in which one or several amino acids are deleted, substituted or added in the amino acid sequences of SEQ ID NOs: 1 to 3, respectively.
- CDRs 1 to 3 are amino acid sequences of SEQ ID NOs: 4 to 6 or amino acid sequences of SEQ ID NOs: 4 to 6, respectively, wherein one or several amino acids are deleted, substituted, or added to the light chain variable region.
- CDRs 1 to 3 each have a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 1 to 3, and CDRs 1 to 3 each comprise a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 4 to 6,
- the anti-human DNAM-1 monoclonal antibody or antibody fragment described in (1) The anti-human DNAM-1 monoclonal antibody or antibody fragment described in (1).
- An immunosuppressant comprising the anti-human DNAM-1 monoclonal antibody or antibody fragment according to any one of (1) to (4) as an active ingredient.
- the immunosuppressive agent according to (8) which is a preventive or therapeutic agent for graft-versus-host disease.
- the immunosuppressive agent according to (8) which is a preventive or therapeutic agent for organ transplant rejection.
- FIG. 3 is a diagram showing the results of alignment of amino acid sequences of heavy chains 1-6.
- FIG. 3 is a diagram showing the results of aligning amino acid sequences of 1 to 6 light chains.
- (A) to (d) are graphs showing the results of Experimental Example 2.
- (A) to (l) are graphs showing the results of Experimental Example 3.
- (A) to (e) are the same as those in Experimental Example 4, except that anti-human DNAM-1 monoclonal antibody No. 6 is a graph showing the results of examining the reactivity of 1 to 6.
- A) to (e) are the same as those in Experimental Example 5, except that anti-human DNAM-1 monoclonal antibody No.
- FIG. 6 is a graph showing the results of examining the reactivity of 1 to 6.
- A) to (e) are the same as those in Experimental Example 6, except that the anti-human DNAM-1 monoclonal antibody No. 6 is a graph showing the results of examining the reactivity of 1 to 6.
- A) to (e) are the same as those in Experimental Example 7, except that the anti-human DNAM-1 monoclonal antibody No. 6 is a graph showing the results of examining the reactivity of 1 to 6.
- 10 is a graph showing the results of a mixed lymphocyte reaction assay in Experimental Example 8. It is a figure which shows the experimental protocol of Experimental example 9.
- FIG. is a graph which shows the survival rate of the mouse
- FIG. 14 is a graph showing the results of measuring the cytotoxic activity of CD8 + T cells reacted with anti-human DNAM-1 monoclonal antibody in Experimental Example 11.
- A is a monoclonal antibody No. It is a graph which shows the result of having measured the ratio of the regulatory T cell in the CD4 ⁇ +> T cell in the spleen of the mouse
- B shows that monoclonal antibody No.
- FIG. 1 It is a graph which shows the result of having measured the ratio of the regulatory T cell in the CD4 ⁇ +> T cell in the peripheral blood of the mouse
- (A) is a graph which shows the result of having measured the incidence rate of encephalomyelitis in Experimental example 13.
- FIG. Further, (b) is a graph showing the results of calculating the average clinical score in Experimental Example 13.
- (A) is a graph showing the results of quantifying alkaline phosphatase in serum in Experimental Example 14.
- (B) is a graph showing the results of quantifying total bilirubin in serum in Experimental Example 14.
- (A) is a photomicrograph of liver tissue of a control mouse in Experimental Example 14.
- (B) is a micrograph of liver tissue of DNAM-1 gene-deficient mice in Experimental Example 14.
- (A) is a photograph of a cut surface of a kidney stained with Masson trichrome in Experimental Example 15.
- (B) is a graph which shows the result of having measured the area of the renal cortex based on (a).
- (A) is a photomicrograph showing typical results of immunostaining of a tissue section of a kidney of a control mouse with anti- ⁇ -SMA antibody in Experimental Example 15.
- (B) is a photomicrograph showing representative results of immunostaining a kidney tissue section of a DNAM-1 gene-deficient mouse in Example 15 with an anti- ⁇ -SMA antibody.
- (C) is a graph showing the results of calculating the area of the ⁇ -SMA positive region in the kidney tissue of each group of mice in Experimental Example 15.
- it is a graph which shows the result of having measured the body weight of the control mouse
- (A) is a photograph of the large intestine of a DNAM-1 gene-deficient mouse excised on the 9th day from the start of the experiment in Experimental Example 16.
- (B) is a photograph of the large intestine of a control mouse excised on the ninth day from the start of the experiment in Experimental Example 16.
- (C) is the graph which digitized the result of (a) and (b).
- the present invention provides an activator of regulatory T cells comprising a substance that inhibits the binding of DNAM-1 and CD155.
- regulatory T cells can be activated by inhibiting the binding between DNAM-1 and CD155. Therefore, a substance that inhibits the binding of DNAM-1 and CD155 can be used for the activation of regulatory T cells.
- the specific binding substance for DNAM-1 and the specific binding substance for CD155 are not particularly limited as long as they can inhibit the binding of DNAM-1 and CD155, and examples thereof include antibodies, antibody fragments, and aptamers.
- the antibody may be prepared by immunizing an animal such as a mouse, or may be prepared by screening an antibody library such as a phage library.
- antibody fragments include F (ab ') 2, Fab', Fab, Fv, scFv and the like.
- Examples of aptamers include nucleic acid aptamers and peptide aptamers.
- the DNAM-1 expression inhibitor and CD155 expression inhibitor are not particularly limited as long as they are substances that can reduce the expression of DNAM-1 or CD155 and consequently inhibit the binding of DNAM-1 and CD155.
- siRNA examples include shRNA, miRNA, ribozyme, antisense nucleic acid, low molecular weight compound and the like.
- siRNA, shRNA, miRNA, ribozyme and antisense nucleic acid may contain various chemical modifications in order to improve stability and activity.
- the phosphate residue may be substituted with a chemically modified phosphate residue such as phosphorothioate, methylphosphonate, phosphorodithionate and the like.
- you may comprise at least one part with nucleic acid analogs, such as a peptide nucleic acid (PNA).
- PNA peptide nucleic acid
- activation of regulatory T cells means an increase in the number of regulatory T cells, an increase in the expression level of inhibitory cytokines such as TGF- ⁇ and IL-10 expressed by regulatory T cells, It means suppression of immune response by T cells, suppression of overall immune response, and the like.
- the activator of regulatory T cells of the present embodiment can be used for the prevention or treatment of diseases whose symptoms can be reduced by the activation of regulatory T cells.
- diseases include graft-versus-host disease, organ transplant rejection, autoimmune disease, fibrotic disease, inflammatory bowel disease, allergy and the like.
- examples of the autoimmune disease include rheumatism, type I diabetes, autoimmune encephalomyelitis and the like.
- Fibrotic diseases are diseases in which tissues are replaced with type I collagen in various organs such as the lung, heart, liver, and kidney, and examples include cirrhosis, diabetic nephropathy, and pulmonary fibrosis.
- Examples of allergies include allergic rhinitis and atopic dermatitis.
- the activator of regulatory T cells of this embodiment may be, for example, a specific binding substance for DNAM-1, and the specific binding substance may be an antibody or a fragment thereof.
- DNAM-1 may be DNAM-1 of a target species that activates regulatory T cells, for example, human DNAM-1. That is, the activator of regulatory T cells of this embodiment may be an anti-human DNAM-1 antibody or a fragment thereof.
- Human DNAM-1 molecule present on the cell surface of the above lymphocytes in terms of the total length of the IgG type antibody of 100 ng or less, preferably 80 ng or less, more preferably 50 ng or less, still more preferably 40 ng or less, particularly preferably 30 ng or less.
- the anti-human DNAM-1 antibody having such reactivity has high ability to activate regulatory T cells.
- the reactivity may be calculated in terms of the total mass of the IgG type antibody.
- the mass may be converted based on the molecular weight of the antibody fragment and the total length of the IgG type antibody.
- the anti-human DNAM-1 antibody or fragment thereof suitable as an activator of regulatory T cells of the present embodiment is present on the surface of 1 ⁇ 10 5 lymphocyte cells in which human DNAM-1 is forcibly expressed.
- the human DNA M-1 molecule is saturated with 1000 ng of a fusion protein of human CD155 and IgG antibody constant region and then reacted with the above lymphocytes, it is 500 ng or less in terms of the total length of IgG antibody, preferably Is not more than 400 ng, more preferably not more than 300 ng, still more preferably not more than 200 ng, particularly preferably not more than 100 ng, and completely inhibits the binding between the fusion protein and the human DNA M-1 molecule present on the cell surface of the lymphocyte. It may be reactive.
- the anti-human DNAM-1 antibody having such a reactivity can release this binding even when DNAM-1 and CD155 are previously bound.
- the anti-human DNAM-1 antibody having such reactivity has high ability to activate regulatory T cells.
- complete inhibition means that it can be substantially completely inhibited.
- This means that the above can be dissociated and bind to the human DNA M-1 molecule present on the cell surface of lymphocytes.
- the activator of regulatory T cells of this embodiment may be an anti-human CD155 antibody or a fragment thereof.
- the anti-human DNAM-1 antibody or fragment thereof, or the anti-human CD155 antibody or fragment thereof is preferably a human type antibody or fragment thereof.
- the chimeric antibody means an antibody in which the variable region is an antibody derived from a non-human animal and at least a part of the constant region is an antibody derived from human.
- the humanized antibody means an antibody in which only the complementarity determining regions (CDRs) of the heavy chain and the light chain are antibodies derived from non-human animals, and the constant region and the framework region are antibodies derived from humans.
- CDRs complementarity determining regions
- a fully human antibody means an antibody derived entirely from a human including a complementarity determining region.
- CDR1 or CDR2 of the heavy chain variable region means four, three or two.
- CDR3 of a heavy chain variable region means two.
- CDR1 or CDR3 of the light chain variable region means four, three or two.
- CDR2 of the light chain variable region means two.
- CDR1 to CDR3 each comprise a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 1 to 3, and CDR1 to CDR3.
- the target antibody is competing with, for example, a monoclonal antibody described later in Examples in the human DNAM-1 molecule present on the surface of 1 ⁇ 10 5 lymphocytes forcibly expressing human DNAM-1. No.
- the antibody of interest is reacted with the lymphocytes described above after reacting with the monoclonal antibody No. This means that at least a part of the bond between 1 and the human DNA M-1 molecule can be dissociated to bind to the human DNA M-1 molecule.
- At least one part may be 10% or more of the whole human DNAM-1 molecule existing on the surface of 1 ⁇ 10 5 lymphocyte cells, or 30% or more, It may be 50% or more, 70% or more, or 90% or more.
- the pharmaceutically acceptable carrier those generally used for preparations can be used, and examples thereof include excipients, stabilizers, solvents for injections, and the like.
- the solvent for injection include isotonic solutions containing adjuvants such as physiological saline, glucose, D-sorbitol, D-mannose, D-mannitol and sodium chloride.
- the pharmaceutical composition of the present embodiment may contain additives in addition to the above-mentioned activator of regulatory T cells and a pharmaceutically acceptable carrier.
- additives include pH adjusters, viscosity improvers, coloring agents, steroids, immunosuppressants and the like conventionally used in the treatment of graft-versus-host disease and organ transplant rejection.
- the pharmaceutical composition of this embodiment is administered to a patient by intravenous administration or the like, for example, as an injection or an infusion.
- the dosage, administration route, and prescription may be appropriately determined according to the patient's symptoms, body weight, age, sex, and the like.
- the dosage of the pharmaceutical composition of the present embodiment varies depending on the patient's symptoms, body weight, age, sex, etc., and cannot be determined unconditionally, but for a human patient requiring treatment per kg body weight in a single administration
- the amount of the active ingredient for example, from 1 ⁇ g to 100 mg, for example from 50 ⁇ g to 50 mg, may be administered once to several times per day.
- the anti-human DNAM-1 antibody having such reactivity is used to activate regulatory T cells, graft versus host disease, organ transplant rejection, autoimmune disease, fibrotic disease, It is useful for reducing symptoms such as inflammatory bowel disease.
- the reactivity may be calculated in terms of the total mass of the IgG type antibody.
- the mass may be converted based on the molecular weight of the antibody fragment and the total length of the IgG type antibody.
- the anti-human DNA M-1 monoclonal antibody or fragment thereof of the present embodiment may be obtained by removing any known antibody and fragment thereof.
- the total length of the IgG antibody is 500 ng or less, preferably 400 ng or less, more preferably 300 ng or less, even more preferably Is not more than 200 ng, particularly preferably not more than 100 ng, and has a reactivity capable of completely inhibiting the binding between the fusion protein and the human DNA M-1 molecule present on the cell surface of the lymphocyte. Also good.
- the anti-human DNAM-1 antibody having such a reactivity can release this binding even when DNAM-1 and CD155 are previously bound.
- “completely inhibit” is the same as described above.
- CDR1 or CDR2 of the heavy chain variable region means four, three or two.
- CDR3 of a heavy chain variable region means two.
- CDR1 or CDR3 of the light chain variable region means four, three or two.
- CDR2 of the light chain variable region means two.
- antibody fragments include Fab, F (ab ′) 2 , single-chain Fv (scFv) in which a heavy chain variable region and a light chain variable region are linked with an appropriate linker, and the like.
- scFv linker include peptides such as (GGGGS) 3 (SEQ ID NO: 21).
- the anti-human DNAM-1 monoclonal antibody or fragment thereof of this embodiment binds well to human DNAM-1 protein and can suppress human immune responses in vivo and in vitro. For this reason, it can utilize as an immunosuppressant.
- CDRs 1 to 3 are each a heavy chain variable region consisting of the amino acid sequence of SEQ ID NOs: 1 to 3
- CDR1-3 may be an antibody that competes with an antibody having a light chain variable region consisting of the amino acid sequences of SEQ ID NOs: 4-6, respectively, or a fragment thereof. That is, the anti-human DNAM-1 antibody is related to the monoclonal antibody No. described later in Examples in connection with the binding to human DNAM-1. It may be an antibody that competes with 1. Monoclonal antibody no. Antibody that competes with monoclonal antibody No. 1 for binding to human DNA M-1. Reactivity equal to or higher than 1. Here, antibody competition is the same as described above.
- the anti-human DNAM-1 monoclonal antibody or fragment thereof has a heavy chain variable region in which CDR1 to 3 are each composed of amino acid sequences of SEQ ID NOs: 1 to 3, and CDR1 to 3 are each composed of amino acid sequences of SEQ ID NOs: 4 to It may have a light chain variable region.
- Examples of such antibodies include monoclonal antibody No. described later in the Examples. 1, monoclonal antibody no. Examples include antibodies in which 1 is humanized.
- the anti-human DNA M-1 monoclonal antibody or fragment thereof may have a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 7 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 8. .
- Examples of such antibodies include monoclonal antibody No. described later in the Examples. 1, monoclonal antibody no. Examples include antibodies in which 1 is humanized.
- the anti-human DNA M-1 monoclonal antibody or a fragment thereof may have a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 9 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 10.
- Examples of such antibodies include monoclonal antibody No. described later in the Examples. 2, monoclonal antibody no. Examples include antibodies in which 2 is humanized.
- the anti-human DNAM-1 monoclonal antibody or a fragment thereof has reactivity with human DNAM-1, one or several amino acids in the amino acid sequence of SEQ ID NO: 7 have been deleted, substituted or added. It may have a heavy chain variable region comprising an amino acid sequence, and a light chain variable region comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence of SEQ ID NO: 8. .
- the anti-human DNAM-1 monoclonal antibody or a fragment thereof has reactivity with human DNAM-1, one or several amino acids in the amino acid sequence of SEQ ID NO: 9 have been deleted, substituted or added. It may have a heavy chain variable region comprising an amino acid sequence and a light chain variable region comprising an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence of SEQ ID NO: 10. .
- nucleic acid encoding anti-human DNAM-1 monoclonal antibody or fragment thereof In one embodiment, the present invention provides a nucleic acid encoding the above-described anti-human DNAM-1 monoclonal antibody or fragment thereof.
- Gene encoding heavy chain variable region and part of constant region of the above, gene encoding light chain variable region and part of constant region of the anti-human DNA M-1 monoclonal antibody described above, anti-human DNA M-1 monoclonal antibody described above A gene encoding the full length of the above heavy chain, a gene encoding the full length of the light chain of the above-mentioned anti-human DNA M-1 monoclonal antibody, and a heavy chain variable region and a light chain variable region of the above-mentioned anti-human DNA M-1 monoclonal antibody appropriately Examples include a gene encoding scFv linked by a linker.
- the above heavy chain variable region gene may be a gene consisting of the base sequence set forth in SEQ ID NO: 19.
- the light chain variable region gene may be a gene consisting of the nucleotide sequence set forth in SEQ ID NO: 20.
- CDRs 1 to 3 are each composed of the amino acid sequences set forth in SEQ ID NOs: 1 to 3, and a framework region other than CDRs encodes a heavy chain variable region derived from a non-mouse antibody. It may be a gene.
- CDRs 1 to 3 each have the amino acid sequence set forth in SEQ ID NOs: 4 to 6, and the framework region other than the CDRs encodes a light chain variable region derived from a non-mouse antibody. It may be a gene.
- examples of non-mouse antibodies include human antibodies.
- the nucleic acid of the present embodiment includes the above-described heavy chain variable region gene of an anti-human DNAM-1 monoclonal antibody or a gene derived therefrom, and the light chain variable region gene of an anti-human DNAM-1 monoclonal antibody or a gene derived therefrom. It is preferable that it is the combination of these.
- CDR1 to CDR3 are each composed of the amino acid sequences set forth in SEQ ID NOs: 1 to 3, and a framework region other than the CDR is derived from a non-mouse antibody-derived heavy chain. And a gene encoding the chain variable region.
- CDR1 to CDR3 are each composed of the amino acid sequences set forth in SEQ ID NOs: 4 to 6, and the framework region other than the CDR is derived from a non-mouse antibody. Examples include a gene encoding a light chain variable region.
- a DNA encoding a tag sequence such as a histidine tag, a FLAG tag, or a GST tag may be added to the 5 ′ end or 3 ′ end of the nucleic acid described above.
- the above expression vector includes an anti-human DNAM in a protein translation system comprising a cell-based vector for expressing an anti-human DNAM-1 monoclonal antibody or a fragment thereof in a host cell and a component capable of synthesizing protein extracted from an appropriate cell.
- Escherichia coli examples include ColE-type plasmids typified by pBR322 derivatives, pACYC-type plasmids having a p15A origin, pSC-type plasmids, and Bac-type F factor-derived mini-F plasmids.
- expression vectors having tryptophan promoters such as trc and tac, lac promoter, T7 promoter, T5 promoter, T3 promoter, SP6 promoter, arabinose inducible promoter, cold shock promoter, tetracycline inducible promoter and the like can be mentioned.
- vectors other than Escherichia coli examples include pAUR plasmids for yeast expression, pIEx plasmids for insect cell expression, pBApo-CMV plasmids for animal cell expression, and the like.
- the cell-free vector examples include an expression vector having a T7 promoter and an expression vector having a T3 promoter mentioned in the cell-based vector; a vector for wheat cell-free protein synthesis such as a pEU-based plasmid having an SP6 promoter or a T7 promoter. It is done.
- the SesA gene is transcribed using a transcription system to synthesize mRNA.
- the transcription system include conventionally known ones that are transcribed by RNA polymerase.
- the RNA polymerase include T7 RNA polymerase and SP6 polymerase.
- the cell-free protein synthesis system which is a translation system, is used to translate the mRNA and synthesize the protein.
- This system contains elements necessary for translation, such as ribosomes, translation initiation factors, translation elongation factors, dissociation factors, and aminoacyl-tRNA synthetases.
- protein translation systems include Escherichia coli extract, rabbit reticulocyte extract, and wheat germ extract.
- the elements necessary for the translation are composed solely of independently purified factors.
- An anti-human DNA M-1 monoclonal antibody or a fragment thereof can be purified from a protein synthesized using a cell-based vector or a cell-free vector.
- the purification method include a method using protein A, protein G and the like. If the expression vector is designed to express a tag sequence such as a histidine tag at the N-terminus or C-terminus of the target protein, use an affinity column that uses a substance having an affinity for this tag, such as nickel or cobalt. A purification method is mentioned.
- the purity of the anti-human DNAM-1 monoclonal antibody or a fragment thereof can be increased by purifying by appropriately combining ion exchange chromatography or gel filtration chromatography.
- the present invention provides a transformant containing the above-described recombinant vector.
- An anti-human DNAM-1 monoclonal antibody or a fragment thereof can be produced from the transformant of the present embodiment or a medium thereof.
- the transformant of this embodiment can be obtained by introducing the above-described recombinant vector into a host.
- the transformant include cultured cells such as Escherichia coli, yeast, plant cells, insect cells, and animal cells into which the above-described recombinant vector has been introduced; insect living organisms such as silkworm into which the above-described vector has been introduced; Examples include plants such as tobacco, into which the vector is introduced.
- Introduction of the recombinant vector into the host can be performed using a conventionally known method.
- a competent cell method using microbial cells treated with calcium, an electroporation method, and the like can be mentioned.
- a method of transforming a host by infecting a phage vector, virus vector or the like may be used.
- the present invention provides an immunosuppressant comprising the above-described anti-human DNAM-1 monoclonal antibody or fragment thereof as an active ingredient.
- the immunosuppressive agent of the present embodiment can suppress the proliferation of CD8 + T cells in a mixed lymphocyte reaction (MLR) assay.
- MLR mixed lymphocyte reaction
- the immunosuppressive agent of the present embodiment has been confirmed to be effective in both prevention and treatment of graft-versus-host disease in a graft-versus-host disease mouse model. .
- the immunosuppressive agent of the present embodiment may be a pharmaceutical composition containing a pharmaceutically acceptable carrier and other additives.
- pharmaceutically acceptable carriers include excipients, stabilizers, solvents for injections, and the like.
- solvent for injection include isotonic solutions containing adjuvants such as physiological saline, glucose, D-sorbitol, D-mannose, D-mannitol and sodium chloride.
- Other additives include, for example, pH adjusters, viscosity improvers, colorants, steroids, immunosuppressants and the like conventionally used in the treatment of graft-versus-host disease and organ transplant rejection.
- the dosage form of the immunosuppressive agent or the above pharmaceutical composition of the present embodiment is not limited, and examples thereof include a lyophilization agent, a powder formulation, a solution formulation with a pH adjusted buffer, and a microcapsule for injection.
- the present invention provides a method of activating regulatory T cells comprising administering an effective amount of a DNAM-1 and CD155 binding inhibitor to a patient in need of treatment.
- a DNAM-1 and CD155 binding inhibitor examples include those described above.
- the present invention provides the use of a DNAM-1 and CD155 binding inhibitor to produce an activator of regulatory T cells.
- a DNAM-1 and CD155 binding inhibitor examples include those described above.
- the present invention provides a DNAM-1 and CD155 binding inhibitor for the prevention or treatment of graft-versus-host disease, organ transplant rejection, autoimmune disease, fibrotic disease, inflammatory bowel disease or allergy.
- a DNAM-1 and CD155 binding inhibitor for the prevention or treatment of graft-versus-host disease, organ transplant rejection, autoimmune disease, fibrotic disease, inflammatory bowel disease or allergy.
- Examples of the binding inhibitor of DNAM-1 and CD155 include those described above.
- the present invention relates to DNAM-1 and CD155 for producing a prophylactic or therapeutic agent for graft-versus-host disease, organ transplant rejection, autoimmune disease, fibrotic disease, inflammatory bowel disease or allergy.
- DNAM-1 and CD155 for producing a prophylactic or therapeutic agent for graft-versus-host disease, organ transplant rejection, autoimmune disease, fibrotic disease, inflammatory bowel disease or allergy.
- binding inhibitors examples include those described above.
- the present invention provides for the treatment of graft-versus-host disease or organ transplant rejection comprising administering an effective amount of the above-described anti-human DNAM-1 monoclonal antibody or fragment thereof to a patient in need of treatment. Or provide preventive methods.
- the present invention provides the above-described anti-human DNAM-1 monoclonal antibody or fragment thereof for the treatment or prevention of graft-versus-host disease or organ transplant rejection.
- the present invention provides the use of the above-described anti-human DNAM-1 monoclonal antibody or fragment thereof for the manufacture of a therapeutic or prophylactic agent for graft-versus-host disease or organ transplant rejection.
- Example 1 Preparation of anti-human DNAM-1 monoclonal antibody
- the human DMAM-1 gene was introduced into the BW5147 cell line, which is a mouse lymphocyte, to express the human DMAM-1 protein. Mice were immunized using these cells as antigens, and hybridomas were prepared by conventional methods. Among the obtained hybridoma strains, anti-human DNA M-1 monoclonal antibody No. 1 was used as an index of reactivity with human DNA M-1 protein. Each clone producing 1-6 was obtained.
- FIG. 3 (a) shows monoclonal antibody no. It is a graph which shows the result of having made 1 react.
- FIG. 3 (b) shows that monoclonal antibody No. It is a graph which shows the result of having made 1 react.
- FIG. 3 (c) shows that monoclonal antibody No. It is a graph which shows the result of having made 2 react.
- FIG. 3 (d) shows that monoclonal antibody No. It is a graph which shows the result of having made 2 react.
- CD3 + CD4 + cells CD4 + T cells
- CD3 + CD8 + cells CD8 + T cells
- CD3 ⁇ CD19 + cells B cells
- CD3 ⁇ CD56 + cells NK present in human peripheral blood lymphocytes Cells
- CD3 + CD56 + cells NKT cells
- CD14 + cells CD14 + cells (monocytes). 1 and no. The reactivity of 2 was examined.
- a control IgG1 antibody was used as a control.
- Monoclonal antibody No. 1 against 1 ⁇ 10 5 peripheral blood lymphocytes. 1 and no. 2 were reacted with 100 ng each. The antibody was allowed to react for 30 minutes on ice.
- FIG. 4 (a) shows monoclonal antibody No. 4 against CD4 + T cells. 1 is a result showing a reactivity of 1.
- FIG. 4 (b) shows monoclonal antibody No. 4 against CD8 + T cells. 1 is a result showing a reactivity of 1.
- FIG. 4 (c) shows monoclonal antibody No. 5 against B cells. 1 is a result showing a reactivity of 1.
- FIG. 4 (d) shows monoclonal antibody No. 4 against CD4 + T cells. 2 is a result showing the reactivity of 2.
- FIG. 4 (e) shows monoclonal antibody No. 4 against CD8 + T cells. 2 is a result showing the reactivity of 2.
- FIG. 4 (f) shows monoclonal antibody No. 5 against B cells.
- FIG. 6 (e) is the same as the result of FIG. 6 (d). 2 and monoclonal antibody no. There was a possibility that the epitope was not competing with 6.
- CD8 + T cells were treated with F (ab ′) type 2 monoclonal antibody No. 2 at a saturation level or higher (1 ⁇ g / mL).
- F (ab ′) type 2 monoclonal antibody No. 1 2 or F (ab ′) type 2 control IgG (control) was reacted and then co-cultured with the above dendritic cells.
- FIG. 9 is a graph showing the results of the MLR assay.
- “*” indicates that there is a significant difference at a risk rate of less than 5%.
- monoclonal antibody no. 1 and no. It was revealed that the growth of CD8 + T cells was significantly suppressed when any of the two was added. This result is shown by monoclonal antibody No. 1 and no. 2 indicates that it can affect the function of human T cells.
- FIG. 10 is a diagram showing an experimental protocol of this experiment.
- the day before the start of the experiment 1.2 Gy was irradiated to hCD155Tg / NOG mice (female, 8 weeks old).
- 2.5 ⁇ 10 6 human peripheral blood lymphocytes were transplanted by tail vein injection on the day of the start of the experiment, and 300 ⁇ g / 0.2 mL of F (ab ′) type 2 monoclonal antibody No. 2 was further transplanted.
- PBS phosphate buffer
- changes in body weight and survival rate of mice were measured, and symptoms of graft-versus-host disease were measured.
- the same amount of antibody was intraperitoneally administered on days 3, 7, 11, 14, 18 and 21 from the start of the experiment.
- FIG. 11 is a graph showing the survival rate of mice. As a result, monoclonal antibody no. The survival rate was significantly increased in the mice to which 1 was administered. This result is shown by monoclonal antibody No. It shows that graft-versus-host disease can be prevented by administering 1.
- ALT glutamate pyruvate transaminase
- AST glutamate oxaloacetate transaminase
- FIG. 12 (a) is a graph showing the results of measuring ALT activity.
- FIG.12 (b) is a graph which shows the result of having measured AST activity.
- monoclonal antibody no It was revealed that the decrease in liver function was suppressed in the mice administered with 1.
- Example 10 (Functional analysis of anti-human DNAM-1 monoclonal antibody 3) Using the same graft versus host disease mouse model as in Experimental Example 9, the monoclonal antibody No. 1 prepared in Experimental Example 1 was used. One function was analyzed. The experimental protocol was changed from that in Experimental Example 9, and monoclonal antibody No. The therapeutic effect of graft-versus-host disease by 1 was examined.
- FIG. 13 is a diagram showing an experimental protocol of this experiment.
- the day before the start of the experiment 1.2 Gy was irradiated to hCD155Tg / NOG mice (female, 8 weeks old).
- 2.5 ⁇ 10 6 human peripheral blood lymphocytes were transplanted by tail vein injection on the day of the start of the experiment.
- changes in body weight and survival rate of mice were measured, and symptoms of graft-versus-host disease were measured.
- 300 ⁇ g / 0.2 mL of F (ab ′) type 2 monoclonal antibody No. 1 was administered intraperitoneally. Monoclonal antibody no. Administration of 1 was continued twice a week until the mice died.
- mice administered with PBS instead of antibody were used.
- FIG. 14 is a graph showing the survival rate of mice. As a result, monoclonal antibody no. The survival rate was significantly increased in the mice to which 1 was administered. This result is shown by monoclonal antibody No. 1 shows that administration of 1 can treat graft-versus-host disease.
- activated CD8 + T cells were treated with control IgG1 antibody (control), monoclonal antibody No. 1 or monoclonal antibody no. 2 was added at a rate of 10 mg / 10 6 cells and allowed to bind by incubating at 4 ° C. for 30 minutes.
- hCD155-expressing cells cells in which hCD155 was forcibly expressed in BW5147 cells were used.
- CD8 + T cells of cytotoxic activity was evaluated by expression of CD107a in CD8 + T cells.
- CD107a is a degranulation marker for CD8 + T cells.
- PBS phosphate buffer
- FIG. 16 (a) shows monoclonal antibody no. It is a graph which shows the result of having measured the ratio of the regulatory T cell in the CD4 ⁇ +> T cell in the spleen of the mouse
- mice 50 ⁇ g / 0.2 mL of myelin oligodendrocyte glycoprotein (MOG) protein corresponding to the 33rd to 55th amino acid sequence was subcutaneously administered to the back of each group of mice.
- MOG myelin oligodendrocyte glycoprotein
- 200 ng / 0.2 mL of pertussis toxin was intraperitoneally administered.
- 200 ng / 0.2 mL of pertussis toxin was intraperitoneally administered to each group of mice.
- mice after the start of the experiment were observed, and the incidence of encephalomyelitis and clinical score were measured.
- the clinical score was the average of the scores evaluated according to the following evaluation criteria. (Clinical score) 0: Normal 1: Reduced tonus of the tail 2: Complete drooping of the tail 3: Abnormal gait 4: Complete weakness of the hind limbs 5: Complete weakness of the hind limbs including forelimb paralysis 6: Death
- FIG. 17 (a) is a graph showing the results of measuring the incidence of encephalomyelitis.
- FIG. 17B is a graph showing the results of calculating the average clinical score.
- the horizontal axis indicates the time (day) after the start of the experiment.
- liver fibrosis was examined using a DNAM-1 gene deficient (hereinafter sometimes referred to as “DNAM-1KO”) mouse. Wild type mice were used as controls. The experiment used a bill duct ligation (BDL) model.
- DNAM-1KO DNAM-1 gene deficient mice
- each group of mice was laparotomized, and the common bile duct was connected to create a BDL model. Subsequently, orbital blood was collected from each group of mice on days 3, 7, 14, and 21 from the start of the experiment. Subsequently, serum was separated from the collected blood, and alkaline phosphatase and total bilirubin were quantified using a clinical chemistry analyzer (model “Drychem”, Fujifilm). Alkaline phosphatase and total bilirubin are indicators of liver and biliary tract disorders.
- mice in each group were perfused systemically and the liver was removed.
- the excised liver was fixed and embedded in paraffin to prepare a tissue section, stained with sirius red, and observed with a microscope.
- Sirius red is a dye that binds to a collagen triple-stranded helix.
- FIG. 18 (a) is a graph showing the results of quantifying alkaline phosphatase in serum.
- WT indicates the result of the wild-type mouse
- DNAM-1 KO indicates the result of the DNAM-1 gene-deficient mouse
- naive indicates the bile duct tuberculosis. It shows that it is the result of the mouse
- the horizontal axis indicates the time (day) after the start of the experiment. As a result, it was revealed that the amount of alkaline phosphatase in the serum of the DNAM-1 gene-deficient mice was significantly smaller than that of the control wild type mice.
- FIG. 18 (b) is a graph showing the results of quantifying total bilirubin in serum.
- WT indicates the result of the wild type mouse
- DNAM-1 KO indicates the result of the DNAM-1 gene-deficient mouse
- naive indicates the bile duct tuberculosis. It shows that it is the result of the mouse
- the horizontal axis indicates the time (day) after the start of the experiment. As a result, it was clarified that DNAM-1 gene-deficient mice have significantly less serum total bilirubin than wild-type mice.
- FIGS. 19A and 19B are micrographs of liver tissue.
- FIG. 19 (a) is a photograph of a control wild type mouse (WT)
- FIG. 19 (b) is a photograph of a DNAM-1 gene-deficient mouse (DNAM-1 KO). The magnification is 20 times in all cases. As a result, it was revealed that liver fibrosis was significantly reduced in DNAM-1 gene-deficient mice compared to wild-type mice.
- each group of mice was laparotomized, and the right renal ureter was tied to create a UUO model. On the other hand, the left kidney was not treated. Subsequently, on the seventh day from the start of the experiment, the mice of each group were perfused systemically and both kidneys were removed. Subsequently, the excised kidney was fixed in formalin and embedded in paraffin to prepare a tissue section. Subsequently, the tissue sections were stained with Masson trichrome and observed. In addition, paraformaldehyde-fixed kidneys were embedded with OCT compound to prepare tissue sections. Subsequently, tissue sections were immunostained, and the area of an ⁇ -smooth muscle actin ( ⁇ -SMA) positive region, which is one of fibrosis indicators, was calculated.
- ⁇ -SMA ⁇ -smooth muscle actin
- FIG. 20 (a) is a photograph of the cut section of the kidney stained with Masson trichrome.
- FIG.20 (b) is a graph which shows the result of having measured the area of the renal cortex based on Fig.20 (a). 20 (a) and 20 (b), “UUO” indicates the result of the right kidney with the ureters connected, “CON” indicates the result of the untreated left kidney, “WT” indicates the result of the wild-type mouse, and “DNAM-1 KO” indicates the result of the DNAM-1 gene-deficient mouse.
- UUO indicates the result of the right kidney with the ureters connected
- CON indicates the result of the untreated left kidney
- WT indicates the result of the wild-type mouse
- DNAM-1 KO indicates the result of the DNAM-1 gene-deficient mouse.
- FIGS. 21A and 21B are photomicrographs showing the results of immunostaining of a kidney tissue section with an anti- ⁇ -SMA antibody.
- FIG. 21 (a) shows a representative result of a tissue section of the right kidney in which a ureter was tied in a control wild type mouse
- FIG. 21 (b) shows a ureter in a DNAM-1 gene-deficient mouse. Shown is a representative result of a tissue section of the right kidney that was tied.
- FIG. 21 (c) is a graph showing the results of calculating the area of the ⁇ -SMA positive region in the kidney tissue of each group of mice.
- FIG. 22 is a graph showing the results of measuring the body weights of control wild-type mice (WT) and DNAM-1 gene-deficient mice (KO).
- WT wild-type mice
- KO DNAM-1 gene-deficient mice
- “*” indicates that there is a significant difference when the risk rate is less than 5%.
- the horizontal axis indicates the time (day) after the start of the experiment. As a result, it was revealed that the weight loss due to inflammatory enteritis was significantly reduced in the DNAM-1 gene-deficient mice compared to the wild-type mice.
- FIG. 23 (a) is a photograph of the large intestine of a DNAM-1 gene-deficient mouse excised on the ninth day from the start of the experiment.
- FIG. 23B is a photograph of the large intestine of a control wild-type mouse excised on the ninth day from the start of the experiment.
- FIG. 23C is a graph in which the results of FIGS. 23A and 23B are digitized.
- WT indicates the result of the wild-type mouse
- “DNAM-1 KO” indicates the result of the DNAM-1 gene-deficient mouse
- “naive” Indicates that the results are for mice given water instead of 2% DSS aqueous solution.
- “NS” indicates that there was no significant difference. As a result, it was revealed that shortening of the intestinal tract due to inflammatory enteritis was significantly reduced in the DNAM-1 gene-deficient mice compared to the wild-type mice.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[1]DNAM-1及びCD155の結合を阻害する物質からなる、制御性T細胞の活性化剤。
[2]DNAM-1及びCD155の結合を阻害する前記物質が、DNAM-1に対する特異的結合物質、DNAM-1発現阻害剤、CD155に対する特異的結合物質又はCD155発現阻害剤である、[1]に記載の制御性T細胞の活性化剤。
[3]移植片対宿主病、臓器移植拒絶、自己免疫疾患、線維化疾患、炎症性腸炎若しくはアレルギーの予防又は治療用である、[1]又は[2]に記載の制御性T細胞の活性化剤。
[4]DNAM-1及びCD155の結合を阻害する前記物質が、DNAM-1対する特異的結合物質であり、前記DNAM-1はヒトDNAM-1であり、前記特異的結合物質は抗体又はその断片であり、前記抗体又はその断片は、ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子と反応させた場合に、IgG型抗体全長に換算して100ng以下で前記ヒトDNAM-1分子を飽和することができる、[1]~[3]のいずれかに記載の制御性T細胞の活性化剤。
[5]DNAM-1及びCD155の結合を阻害する前記物質が、DNAM-1対する特異的結合物質であり、前記DNAM-1はヒトDNAM-1であり、前記特異的結合物質は抗体又はその断片であり、前記抗体又はその断片は、ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子を、ヒトCD155とIgG型抗体定常領域との融合タンパク質1000ngで飽和させた後に反応させた場合に、IgG型抗体全長に換算して500ng以下で、前記融合タンパク質と前記ヒトDNAM-1分子との結合を完全に阻害することができる、[1]~[4]のいずれかに記載の制御性T細胞の活性化剤。
[6]前記抗体はヒト型抗体である、[4]又は[5]に記載の制御性T細胞の活性化剤。
[7]前記抗体又はその断片は、相補性決定領域(CDR)1~3が、それぞれ配列番号1~3のアミノ酸配列又は配列番号1~3のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列又は配列番号4~6のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有するか、又は、ヒトDNAM-1と結合させた場合に、CDR1~3が、それぞれ配列番号1~3のアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列からなる軽鎖可変領域、を有する抗体と競合する、[4]~[6]のいずれかに記載の制御性T細胞の活性化剤。
[8]前記抗体又はその断片は、CDR1~3が、それぞれ配列番号1~3のアミノ酸配列又は配列番号1~3のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列又は配列番号4~6のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、[4]~[7]のいずれかに記載の制御性T細胞の活性化剤。
[9][1]~[8]のいずれかに記載の制御性T細胞の活性化剤と、薬学的に許容できる担体とを含む、制御性T細胞活性化用医薬組成物。
[10]ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子と反応させた場合に、IgG型抗体全長に換算して100ng以下で前記ヒトDNAM-1分子を飽和することができる、抗ヒトDNAM-1モノクローナル抗体又はその断片。
[11]ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子を、ヒトCD155とIgG型抗体定常領域との融合タンパク質1000ngで飽和させた後に反応させた場合に、IgG型抗体全長に換算して500ng以下で、前記融合タンパク質と前記ヒトDNAM-1分子との結合を完全に阻害することができる、抗ヒトDNAM-1モノクローナル抗体又はその断片。
[12]ヒト型抗体又はその断片である、[10]又は[11]に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
[13]CDR1~3が、それぞれ配列番号1~3のアミノ酸配列又は配列番号1~3のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列又は配列番号4~6のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有するか、又は、ヒトDNAM-1と結合させた場合に、CDR1~3が、それぞれ配列番号1~3のアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列からなる軽鎖可変領域、を有する抗体と競合する、[10]~[12]のいずれかに記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
[14]CDR1~3が、それぞれ配列番号1~3のアミノ酸配列又は配列番号1~3のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列又は配列番号4~6のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、[10]~[13]のいずれかに記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
[15]CDR1~3が、それぞれ配列番号1~3のアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列からなる軽鎖可変領域、を有する、[10]~[14]のいずれかに記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
[16]配列番号7のアミノ酸配列又は配列番号7のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、配列番号8のアミノ酸配列又は配列番号8のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、[10]~[15]のいずれか一項に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
[17]配列番号7のアミノ酸配列からなる重鎖可変領域、及び、配列番号8のアミノ酸配列からなる軽鎖可変領域、を有する、[16]に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
[18]配列番号9のアミノ酸配列又は配列番号9のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、配列番号10のアミノ酸配列又は配列番号10のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、[10]~[14]のいずれかに記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
[19]配列番号9のアミノ酸配列からなる重鎖可変領域、及び、配列番号10のアミノ酸配列からなる軽鎖可変領域、を有する、[18]に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
[20][10]~[19]のいずれかに記載の抗ヒトDNAM-1モノクローナル抗体又はその断片をコードする核酸。
[21][20]に記載の核酸を含有するベクター。
[22][21]に記載のベクターを含有する形質転換体。
(2)CDR1~3が、それぞれ配列番号1~3のアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列からなる軽鎖可変領域、を有する、(1)に記載の抗ヒトDNAM-1モノクローナル抗体又は抗体フラグメント。
(3)配列番号7のアミノ酸配列又は配列番号7のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、配列番号8のアミノ酸配列又は配列番号8のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、(1)又は(2)に記載の抗ヒトDNAM-1モノクローナル抗体又は抗体フラグメント。
(4)配列番号7のアミノ酸配列からなる重鎖可変領域、及び、配列番号8のアミノ酸配列からなる軽鎖可変領域、を有する、(1)~(3)のいずれかに記載の抗ヒトDNAM-1モノクローナル抗体又は抗体フラグメント。
(5)(1)~(4)のいずれかに記載の抗ヒトDNAM-1モノクローナル抗体又は抗体フラグメントをコードする核酸。
(6)(5)に記載の核酸を含有する組換えベクター。
(7)(6)に記載の組換えベクターを含有する形質転換体。
(8)(1)~(4)のいずれかに記載の抗ヒトDNAM-1モノクローナル抗体又は抗体フラグメントを有効成分として含有する免疫抑制剤。
(9)移植片対宿主病の予防又は治療剤である、(8)に記載の免疫抑制剤。
(10)臓器移植拒絶の予防又は治療剤である、(8)に記載の免疫抑制剤。
1実施形態において、本発明は、DNAM-1及びCD155の結合を阻害する物質からなる、制御性T細胞の活性化剤を提供する。
1実施形態において、本発明は、上述した制御性T細胞の活性化剤と、薬学的に許容できる担体とを含む、制御性T細胞活性化用医薬組成物を提供する。
1実施形態において、本発明は、ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子と反応させた場合に、IgG型抗体全長に換算して100ng以下、好ましくは80ng以下、より好ましくは50ng以下、更に好ましくは40ng以下、特に好ましくは30ng以下で、上記のリンパ球の細胞表面に存在するヒトDNAM-1分子を飽和することができる、抗ヒトDNAM-1モノクローナル抗体又はその断片を提供する。
1実施形態において、本発明は、上述した抗ヒトDNAM-1モノクローナル抗体又はその断片をコードする核酸を提供する。
1実施形態において、本発明は、上述した核酸を含有する組換えベクターを提供する。本実施形態の組換えベクターは、発現ベクターであってもよい。本実施形態のベクターが発現ベクターである場合、宿主に導入して発現させることにより、抗ヒトDNAM-1モノクローナル抗体又はその断片を製造することができる。
1実施形態において、本発明は、上述した組換えベクターを含有する形質転換体を提供する。本実施形態の形質転換体又はその培地等より、抗ヒトDNAM-1モノクローナル抗体又はその断片を製造することができる。
1実施形態において、本発明は、上述した抗ヒトDNAM-1モノクローナル抗体又はその断片を有効成分として含有する免疫抑制剤を提供する。
1実施形態において、本発明は、DNAM-1及びCD155の結合阻害物質の有効量を、治療を必要とする患者に投与する工程を備える、制御性T細胞の活性化方法を提供する。DNAM-1及びCD155の結合阻害物質としては、上述したものが挙げられる。
(抗ヒトDNAM-1モノクローナル抗体の作製)
マウスリンパ球細胞であるBW5147細胞株にヒトDMAM-1遺伝子を導入し、ヒトDMAM-1タンパク質を発現させた。この細胞を抗原としてマウスを免疫し、常法によりハイブリドーマを作製した。得られたハイブリドーマ株の中からヒトDNAM-1タンパク質に対する反応性を指標として抗ヒトDNAM-1モノクローナル抗体No.1~6を産生するクローンをそれぞれ取得した。
(抗ヒトDNAM-1モノクローナル抗体の反応性の検討1)
実験例1で作製したモノクローナル抗体No.1及びNo.2の反応性を検討した。具体的には、マウスリンパ球細胞であるBW5147細胞株(以下、「BW」という場合がある。)、及びヒトDMAM-1タンパク質を発現させたBW5147細胞株(以下、「DNAM-1/BW」という場合がある。)に、モノクローナル抗体No.1及びNo.2を反応させ、フローサイトメトリー解析を行った。対照にはコントロールIgG1抗体を使用した。1×105個の各細胞に対し、30ngの各抗体を反応させた。抗体は氷上で30分間反応させた。
(抗ヒトDNAM-1モノクローナル抗体の反応性の検討2)
実験例1で作製したモノクローナル抗体No.1及びNo.2のヒト末梢血リンパ球表面に存在するDNAM-1タンパク質に対する反応性を検討した。
(抗ヒトDNAM-1モノクローナル抗体の反応性の検討3)
実験例1で作製したモノクローナル抗体No.1~No.6を用いた競合アッセイを行った。より具体的には、まず、上述したDNAM-1/BW細胞1×105個に対し、100ngのモノクローナル抗体No.2を反応させた(前処理)。続いて、段階希釈したモノクローナル抗体No.1、3~6をそれぞれ反応させた。抗体は氷上で30分間反応させた。前処理なしのDNAM-1/BW細胞に対する各抗体の反応性も検討した。
(抗ヒトDNAM-1モノクローナル抗体の反応性の検討4)
DNAM-1/BW細胞に予め反応させる抗体を入れ替えて、実験例4と同様の実験を行った。より具体的には、まず、上述したDNAM-1/BW細胞1×105個に対し、飽和量のモノクローナル抗体No.1、3~6をそれぞれ反応させた(前処理)。具体的には、モノクローナル抗体No.1を30ng、No.3を300ng、No.4を300ng、No.5を500ng、No.6を1000ng使用した。
(抗ヒトDNAM-1モノクローナル抗体の反応性の検討5)
DNAM-1タンパク質はCD155タンパク質と相互作用することが知られている。そこで、実験例1で作製したモノクローナル抗体No.1~No.6が、DNAM-1タンパク質とCD155タンパク質との相互作用を阻害することができるか否かを検討した。
(抗ヒトDNAM-1モノクローナル抗体の反応性の検討6)
実験例6において、hCD155-Fcタンパク質を予め反応させたDNAM-1/BW細胞に、段階希釈したモノクローナル抗体No.1~No.6をそれぞれ反応させた後、DNAM-1/BW細表面のDNAM-1タンパク質に結合したhCD155-Fcタンパク質を検出した。hCD155-Fcタンパク質の検出は、抗ヒトIgG抗体を用いて行った。反応は氷上で30分間行った。
(抗ヒトDNAM-1モノクローナル抗体の機能解析1)
実験例1で作製したモノクローナル抗体No.1又はNo.2の存在下で混合リンパ球反応(mixed lymphocyte reaction、MLR)アッセイを行い、T細胞の増殖に対するモノクローナル抗体の影響を検討した。
(抗ヒトDNAM-1モノクローナル抗体の機能解析2)
移植片対宿主病マウスモデルを用いて、実験例1で作製したモノクローナル抗体No.1の機能を解析した。
(抗ヒトDNAM-1モノクローナル抗体の機能解析3)
実験例9と同様の移植片対宿主病マウスモデルを用いて、実験例1で作製したモノクローナル抗体No.1の機能を解析した。実験例9とは実験プロトコルを変更し、モノクローナル抗体No.1による移植片対宿主病の治療効果を検討した。
(抗ヒトDNAM-1モノクローナル抗体の機能解析4)
実験例1で作製したモノクローナル抗体No.1とモノクローナル抗体No.2の機能を比較した。より具体的には、まず、ヒト末梢血単核細胞からCD8+T細胞を分離し、抗CD3抗体(型式「555336」、BD Bioscience社、0.25μg/mL)、抗CD28抗体(型式「555725」、BD Bioscience社、1μg/mL)及びIL-2(型式「554603」、BD Bioscience社、0.02μg/mL)の存在下で7日間培養し、活性化した。
(制御性T細胞に関する検討)
実験例9と同様の移植片対宿主病マウスモデルを用いて、実験例1で作製したモノクローナル抗体No.1の機能を解析した。
(自己免疫疾患に関する検討)
実験的自己免疫性脳脊髄炎モデルを用いて抗DNAM-1抗体の機能を評価した。具体的には、まず、実験開始の前日に、C57BL/6Jマウスに100μg/0.2mLの抗マウスDNAM-1抗体を腹腔内投与した(n=8)。また、対照として、C57BL/6Jマウスに100μg/0.2mLのコントロールIgG抗体を腹腔内投与した(n=9)。
(臨床スコア)
0:正常
1:尾のトーヌス低下
2:尾の完全下垂
3:歩行異常
4:後肢の完全脱力
5:前肢麻痺を含む後肢の完全脱力
6:死亡
(肝臓の線維化に関する検討)
抗DNAM-1抗体の投与の代わりにDNAM-1遺伝子欠損(以下、「DNAM-1KO」という場合がある。)マウスを用いて肝臓の線維化に関する検討を行った。対照には野生型マウスを使用した。実験にはbile duct ligation(BDL)モデルを使用した。
(腎臓の線維化に関する検討)
抗DNAM-1抗体の投与の代わりにDNAM-1遺伝子欠損マウスを用いて腎臓の線維化に関する検討を行った。対照には野生型マウスを使用した。実験にはUnilateral ureteral obstruction(UUO)モデルを使用した。
(炎症性腸炎に関する検討)
抗DNAM-1抗体の投与の代わりにDNAM-1遺伝子欠損マウスを用いて炎症性腸炎に関する検討を行った。対照には野生型マウスを使用した。実験にはデキストラン硫酸(DSS)誘導マウス腸炎モデルを使用した。
Claims (22)
- DNAX Accessory Molecule-1(DNAM-1)及びCD155の結合を阻害する物質からなる、制御性T細胞の活性化剤。
- DNAM-1及びCD155の結合を阻害する前記物質が、DNAM-1に対する特異的結合物質、DNAM-1発現阻害剤、CD155に対する特異的結合物質又はCD155発現阻害剤である、請求項1に記載の制御性T細胞の活性化剤。
- 移植片対宿主病、臓器移植拒絶、自己免疫疾患、線維化疾患、炎症性腸炎若しくはアレルギーの予防又は治療用である、請求項1又は2に記載の制御性T細胞の活性化剤。
- DNAM-1及びCD155の結合を阻害する前記物質が、DNAM-1対する特異的結合物質であり、
前記DNAM-1はヒトDNAM-1であり、
前記特異的結合物質は抗体又はその断片であり、
前記抗体又はその断片は、ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子と反応させた場合に、IgG型抗体全長に換算して100ng以下で前記ヒトDNAM-1分子を飽和することができる、
請求項1~3のいずれか一項に記載の制御性T細胞の活性化剤。 - DNAM-1及びCD155の結合を阻害する前記物質が、DNAM-1対する特異的結合物質であり、
前記DNAM-1はヒトDNAM-1であり、
前記特異的結合物質は抗体又はその断片であり、
前記抗体又はその断片は、ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子を、ヒトCD155とIgG型抗体定常領域との融合タンパク質1000ngで飽和させた後に反応させた場合に、IgG型抗体全長に換算して500ng以下で、前記融合タンパク質と前記ヒトDNAM-1分子との結合を完全に阻害することができる、
請求項1~4のいずれか一項に記載の制御性T細胞の活性化剤。 - 前記抗体はヒト型抗体である、請求項4又は5に記載の制御性T細胞の活性化剤。
- 前記抗体又はその断片は、
相補性決定領域(CDR)1~3が、それぞれ配列番号1~3のアミノ酸配列又は配列番号1~3のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列又は配列番号4~6のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有するか、又は
ヒトDNAM-1と結合させた場合に、CDR1~3が、それぞれ配列番号1~3のアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列からなる軽鎖可変領域、を有する抗体と競合する、
請求項4~6のいずれか一項に記載の制御性T細胞の活性化剤。 - 前記抗体又はその断片は、
CDR1~3が、それぞれ配列番号1~3のアミノ酸配列又は配列番号1~3のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列又は配列番号4~6のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、
請求項4~7のいずれか一項に記載の制御性T細胞の活性化剤。 - 請求項1~8のいずれか一項に記載の制御性T細胞の活性化剤と、薬学的に許容できる担体とを含む、制御性T細胞活性化用医薬組成物。
- ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子と反応させた場合に、IgG型抗体全長に換算して50ng以下で前記ヒトDNAM-1分子を飽和することができる、抗ヒトDNAM-1モノクローナル抗体又はその断片。
- ヒトDNAM-1を強制発現させたリンパ球細胞1×105個の細胞表面に存在するヒトDNAM-1分子を、ヒトCD155とIgG型抗体定常領域との融合タンパク質1000ngで飽和させた後に反応させた場合に、IgG型抗体全長に換算して300ng以下で、前記融合タンパク質と前記ヒトDNAM-1分子との結合を完全に阻害することができる、抗ヒトDNAM-1モノクローナル抗体又はその断片。
- ヒト型抗体又はその断片である、請求項10又は11に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
- CDR1~3が、それぞれ配列番号1~3のアミノ酸配列又は配列番号1~3のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列又は配列番号4~6のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有するか、又は
ヒトDNAM-1と結合させた場合に、CDR1~3が、それぞれ配列番号1~3のアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列からなる軽鎖可変領域、を有する抗体と競合する、
請求項10~12のいずれか一項に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。 - CDR1~3が、それぞれ配列番号1~3のアミノ酸配列又は配列番号1~3のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列又は配列番号4~6のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、請求項10~13のいずれか一項に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
- CDR1~3が、それぞれ配列番号1~3のアミノ酸配列からなる重鎖可変領域、及び、CDR1~3が、それぞれ配列番号4~6のアミノ酸配列からなる軽鎖可変領域、を有する、請求項10~14のいずれか一項に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
- 配列番号7のアミノ酸配列又は配列番号7のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、
配列番号8のアミノ酸配列又は配列番号8のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、請求項10~15のいずれか一項に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。 - 配列番号7のアミノ酸配列からなる重鎖可変領域、及び、配列番号8のアミノ酸配列からなる軽鎖可変領域、を有する、請求項16に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
- 配列番号9のアミノ酸配列又は配列番号9のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる重鎖可変領域、及び、
配列番号10のアミノ酸配列又は配列番号10のアミノ酸配列において1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなる軽鎖可変領域、を有する、請求項10~14のいずれか一項に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。 - 配列番号9のアミノ酸配列からなる重鎖可変領域、及び、配列番号10のアミノ酸配列からなる軽鎖可変領域、を有する、請求項18に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片。
- 請求項10~19のいずれか一項に記載の抗ヒトDNAM-1モノクローナル抗体又はその断片をコードする核酸。
- 請求項20に記載の核酸を含有するベクター。
- 請求項21に記載のベクターを含有する形質転換体。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780024787.7A CN109072226B (zh) | 2016-04-20 | 2017-04-19 | 调节性t细胞的激活剂及其应用 |
RU2018140709A RU2736650C2 (ru) | 2016-04-20 | 2017-04-19 | Активатор регуляторных t-клеток и его применение |
IL262227A IL262227B (en) | 2016-04-20 | 2017-04-19 | A regulatory t cell activator and its use |
ES17786002T ES2936075T3 (es) | 2016-04-20 | 2017-04-19 | Activador de células T reguladoras, y uso del mismo |
EP17786002.0A EP3447138B1 (en) | 2016-04-20 | 2017-04-19 | Regulatory t cell activator, and use thereof |
AU2017253320A AU2017253320B2 (en) | 2016-04-20 | 2017-04-19 | Regulatory T cell activator, and use thereof |
CA3021631A CA3021631C (en) | 2016-04-20 | 2017-04-19 | Regulatory t cell activator and use thereof |
JP2018513201A JP6942356B2 (ja) | 2016-04-20 | 2017-04-19 | 制御性t細胞の活性化剤及びその使用 |
US16/095,024 US11059888B2 (en) | 2016-04-20 | 2017-04-19 | Regulatory T cell activator and use thereof |
NZ746977A NZ746977A (en) | 2016-04-20 | 2017-04-19 | Regulatory t cell activator, and use thereof |
KR1020187033489A KR102138998B1 (ko) | 2016-04-20 | 2017-04-19 | 제어성 t 세포의 활성화제 및 그의 사용 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016084170 | 2016-04-20 | ||
JP2016-084170 | 2016-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017183665A1 true WO2017183665A1 (ja) | 2017-10-26 |
Family
ID=60116156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/015767 WO2017183665A1 (ja) | 2016-04-20 | 2017-04-19 | 制御性t細胞の活性化剤及びその使用 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11059888B2 (ja) |
EP (1) | EP3447138B1 (ja) |
JP (1) | JP6942356B2 (ja) |
KR (1) | KR102138998B1 (ja) |
CN (1) | CN109072226B (ja) |
AU (1) | AU2017253320B2 (ja) |
CA (1) | CA3021631C (ja) |
ES (1) | ES2936075T3 (ja) |
IL (1) | IL262227B (ja) |
NZ (1) | NZ746977A (ja) |
RU (1) | RU2736650C2 (ja) |
WO (1) | WO2017183665A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020250593A1 (ja) * | 2019-06-11 | 2020-12-17 | 国立大学法人筑波大学 | 移植片対宿主病(gvhd)の予測方法およびgvhdを予測するコンピュータープログラム |
WO2023112317A1 (ja) | 2021-12-17 | 2023-06-22 | 国立大学法人筑波大学 | ヒト化抗dnam-1抗体 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI728400B (zh) * | 2018-07-26 | 2021-05-21 | 美商美國禮來大藥廠 | Cd226促效劑抗體 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5296530B2 (ja) * | 2006-04-07 | 2013-09-25 | 国立大学法人 筑波大学 | 移植片対宿主病予知マーカーおよびその利用 |
JP2013193995A (ja) * | 2012-03-21 | 2013-09-30 | Tokyo Medical & Dental Univ | 特発性炎症性筋疾患の予防又は治療剤 |
JP2013245162A (ja) * | 2012-05-23 | 2013-12-09 | Univ Of Tsukuba | 同種間での移植心臓、移植血管、または移植腎臓の生着を維持するために用いられる薬剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011156356A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
WO2015009856A2 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
-
2017
- 2017-04-19 IL IL262227A patent/IL262227B/en unknown
- 2017-04-19 KR KR1020187033489A patent/KR102138998B1/ko active IP Right Grant
- 2017-04-19 ES ES17786002T patent/ES2936075T3/es active Active
- 2017-04-19 CA CA3021631A patent/CA3021631C/en active Active
- 2017-04-19 NZ NZ746977A patent/NZ746977A/en unknown
- 2017-04-19 US US16/095,024 patent/US11059888B2/en active Active
- 2017-04-19 EP EP17786002.0A patent/EP3447138B1/en active Active
- 2017-04-19 CN CN201780024787.7A patent/CN109072226B/zh active Active
- 2017-04-19 WO PCT/JP2017/015767 patent/WO2017183665A1/ja active Application Filing
- 2017-04-19 JP JP2018513201A patent/JP6942356B2/ja active Active
- 2017-04-19 AU AU2017253320A patent/AU2017253320B2/en active Active
- 2017-04-19 RU RU2018140709A patent/RU2736650C2/ru active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5296530B2 (ja) * | 2006-04-07 | 2013-09-25 | 国立大学法人 筑波大学 | 移植片対宿主病予知マーカーおよびその利用 |
JP2013193995A (ja) * | 2012-03-21 | 2013-09-30 | Tokyo Medical & Dental Univ | 特発性炎症性筋疾患の予防又は治療剤 |
JP2013245162A (ja) * | 2012-05-23 | 2013-12-09 | Univ Of Tsukuba | 同種間での移植心臓、移植血管、または移植腎臓の生着を維持するために用いられる薬剤 |
Non-Patent Citations (6)
Title |
---|
AKIRA SHIBUYA: "DNAM-1( CD 226) ni yoru Killer Rinpakyu Kasseika to Hyoteki Saibo Shogai", INFECTION, INFLAMMATION & IMMUNITY, vol. 43, no. 4, 2013, pages 24 - 34, XP009513791 * |
KOYAMA,M. ET AL.: "Promoting regulation via the inhibition of DNAM-1 after transplantation", BLOOD, vol. 121, 2013, pages 3511 - 3520, XP055433734 * |
See also references of EP3447138A4 * |
SHIBUYA,A. ET AL.: "DNAM-1, A Novel Adhesion Molecule involved in the Cytolytic Function of T Lymphocytes", IMMUNITY, vol. 4, no. 6, June 1996 (1996-06-01), pages 573 - 581, XP000618600 * |
TAHARA-HANAOKA,S. ET AL.: "Identification and characterization of murine DNAM-1( CD 226) and its poliovirus receptor family ligands", BIOCHAMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 329, no. 3, 15 April 2005 (2005-04-15), pages 996 - 1000, XP004775397 * |
YAMASHITA,Y. ET AL.: "Establishment and Characterization of a novel Anti-DNAM-1 Monoclonal Antibody", MONOCLONAL ANTIBODIES IN IMMUNODIAGNOSIS AND IMMUNOTHERAPY, vol. 32, no. 1, 2013, pages 60 - 64, XP055551019 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020250593A1 (ja) * | 2019-06-11 | 2020-12-17 | 国立大学法人筑波大学 | 移植片対宿主病(gvhd)の予測方法およびgvhdを予測するコンピュータープログラム |
WO2023112317A1 (ja) | 2021-12-17 | 2023-06-22 | 国立大学法人筑波大学 | ヒト化抗dnam-1抗体 |
Also Published As
Publication number | Publication date |
---|---|
RU2736650C2 (ru) | 2020-11-19 |
AU2017253320B2 (en) | 2020-10-22 |
RU2018140709A3 (ja) | 2020-05-20 |
RU2018140709A (ru) | 2020-05-20 |
EP3447138A1 (en) | 2019-02-27 |
KR20180135028A (ko) | 2018-12-19 |
NZ746977A (en) | 2020-07-31 |
CA3021631C (en) | 2023-01-17 |
US20190127462A1 (en) | 2019-05-02 |
EP3447138A4 (en) | 2020-01-01 |
IL262227A (en) | 2018-12-31 |
KR102138998B1 (ko) | 2020-07-29 |
EP3447138B1 (en) | 2022-12-28 |
US11059888B2 (en) | 2021-07-13 |
CN109072226B (zh) | 2021-10-15 |
CN109072226A (zh) | 2018-12-21 |
ES2936075T3 (es) | 2023-03-14 |
JPWO2017183665A1 (ja) | 2019-02-21 |
CA3021631A1 (en) | 2017-10-26 |
AU2017253320A1 (en) | 2018-11-01 |
JP6942356B2 (ja) | 2021-09-29 |
IL262227B (en) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7451627B2 (ja) | キメラ受容体及びその使用方法 | |
JP4212278B2 (ja) | 移植片拒絶反応抑制剤 | |
JP6466401B2 (ja) | ヒト化抗cd19キメラ抗原受容体を使用するがんの処置 | |
US20190046538A1 (en) | Methods for treating gi syndrome and graft versus host disease | |
US11958905B2 (en) | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody | |
TW201938586A (zh) | 雙特異性抗體產品之連續製造製程 | |
JP6942356B2 (ja) | 制御性t細胞の活性化剤及びその使用 | |
JP2024506758A (ja) | 改変された幹細胞組成物およびその使用方法 | |
WO2011013470A1 (ja) | 自己抗体産生阻害剤 | |
TW201806970A (zh) | 嵌合抗原受體、及其利用 | |
US10669335B2 (en) | Blockade of RGMB for reducing transplantation-associated inflammation leading to loss of function of a transplanted organ in a graft recipient | |
US9334326B2 (en) | Antibody that binds domain 2 of ICAM-1 and methods of treatment | |
JP2020503255A (ja) | インテグリンアルファ9の遮断はリンパ弁形成を抑制し、移植片の生存を促進する | |
US20230242666A1 (en) | Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling | |
JP2024522279A (ja) | CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体 | |
KR20240099281A (ko) | 항-steap2 키메라 항원 수용체 및 이의 용도 | |
JP2023504974A (ja) | 抗tirc7抗原結合タンパク質 | |
CN116854819A (zh) | 抗cd25抗体及其应用 | |
MX2008004901A (es) | Agentes para suprimir el daño a islotes trasplantados despues del trasplante del islote. | |
WO2010046474A2 (en) | Chemoattractants inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2018513201 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3021631 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017253320 Country of ref document: AU Date of ref document: 20170419 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20187033489 Country of ref document: KR Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17786002 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017786002 Country of ref document: EP Effective date: 20181120 |